--------------------
human
65–85
hemoconcentration
Cannulation
REF].Thrombosed
Thrombus
Thrombosed
AVGs
AVFs
https://cdt.amegroups.com/article/view/10.21037/cdt-21-523/rc
--------------------
continue
AVGs
AVFs
Thrombectomy
rheolytic
AVGs
AVFs
--------------------
create
Thrombosed
AVGs
AVFs
Thrombectomy
rheolytic
AVGs
AVFs
AVGs
AVFs
--------------------
explain
AVGs
AVFs
--------------------
human
disease-2019
78%.5
CSDH)8
--------------------
continue
--------------------
explain
--------------------
create
disease-2019
--------------------
human
immunoregulation
eATP
eATP
eATP
purinoceptor
eATP
eADO
ectonucleotidases
REF].eADO
signaling.eADO
eATP
ectonucleotidases
eATP
CD39
ectonucleoside
diphosphohydrolase
eADO
CD73
5′-nucleotidase
eAMP
eADO
eAMP
eATP
NDPK
REF].The
eADO
ectohydrolase
CD203a
ectonucleotide
ADPR
CD203a
ADPR
CD73
eADO
CD73
TNAP
eAMP
eADO
REF].Analogous
eATP
eADO
eADO
--------------------
explain
immunoregulation
eATP
eATP
eATP
purinoceptor
eATP
eADO
ectonucleotidases
eADO
eATP
eADO
CD39
CD73
eAMP
eATP
eATP
eADO
CD203a
eAMP
eADO
eADO
eADO
eADO
CD73
--------------------
create
adenosinergic
eADO
eATP
eATP
eADO
immunosurveillance
eATP
eADO
eATP
eADO
eATP
adenosinergic
adenosinergic
adenosinergic
adenosinergic
adenosinergic
adenosinergic
adenosinergic
--------------------
continue
adenosinergic
adenosinergic
eATP
eADO
eATP
eATP
eATP
eADO
ectonucleotidases
CD39
CD73
eATP
eADO
eADO
eADO
adenosinergic
adenosinergic
eATP
eADO
adenosinergic
eATP
adenosinergic
adenosinergic
eATP
eADO
adenosinergic
--------------------
human
REF]).Detailed
sarcopenic
sarcopenic
sarcopenic
--------------------
continue
AgeiNg
ENHANce
sarcopenic
SarQoL
SarQoL
--------------------
create
Jentoft
Jentoft
AgeiNg
ENHANce
--------------------
explain
sarcopenic
sarcopenic
--------------------
create
--------------------
human
PASC.The
https://recovercovid.org/protocols
PASC.The
--------------------
explain
--------------------
continue
